Gujarat Themis Biosyn (BOM:506879) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506879 Gujarat Themis Biosyn Ltd BOM:506879
72 GF Score
Price ₹422.60
GF Value ₹351.33
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Gujarat Themis Biosyn Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

BOM:506879
72GF Score
Gujarat Themis Biosyn Ltd BOM:506879
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gujarat Themis Biosyn (BOM:506879) Overvalued in 2026?

Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued. The current stock price of ₹422.60 is trading 20.3% above its estimated GF Value™ of ₹351.33. GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.

Key valuation signals for BOM:506879:

  • Dividends Received:
  • GF Value™: ₹351.33 vs. price of ₹422.60 (20.3% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the BOM:506879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gujarat Themis Biosyn Business Description

Other Exchanges GUJTHEM:India
Address S.V Road, Themis House, 11/12 Udyog Nagar, Goregaon (West), Mumbai, MH, IND, 400104
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
72GF Score

Get the complete analysis for BOM:506879

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹422.60
Price
₹351.33
GF Value